Empagliflozin for renal insufficiency, chronic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Kidney Failure, Chronic

Why this status

  1. 31 Mar 2022: Trial registered, NCT05305495
  2. 22 Dec 2022: Trial started, NCT05305495

The trials

NCT05305495: Empagliflozin in Acute Heart Failure

State
Completed
Phase
Phase 4
People
25 taking part
Started
22 Dec 2022
Primary completion
15 Feb 2026
Arms
Patients with diuretic resistance
Results
None posted
  1. 31 Mar 2022: Trial registered
  2. 22 Dec 2022: Trial started
  3. 10 Mar 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.